Table II.
Distribution of changes in hormone receptor status at metastatic sites.
| Primary tumor receptor status | ||||||||
|---|---|---|---|---|---|---|---|---|
| Estrogen receptor | Progesterone receptor | |||||||
| Variable | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative |
| Patients (n) | 48 | – | – | 22 | 38 | – | – | 32 |
| Receptor status | ||||||||
| Metastatic lymph nodes from the primaries | ||||||||
| Number of patients (%) | 24 (96.0) | 1 (4.0) | 0 | 5 (100) | 13 (81.2) | 3 (18.8) | 5 (35.7) | 9 (64.3) |
| Metastatic site | ||||||||
| Number of patients (%) | 39 (81.2) | 9 (19.8) | 6 (27.2) | 16 (82.8) | 23 (60.5) | 15 (39.5) | 10 (31.2) | 21 (65.6) |
| Adjuvant treatment, n (%) | ||||||||
| Hormonal treatment only | 17 (43.6) | 4 (44.4) | 0 | 1 (6.2) | 10 (43.5) | 6 (40.0) | 2 (20.0) | 1 (4.8) |
| Hormonal treatment and/or chemotherapy | 19 (48.7) | 5 (55.6) | 6 (100) | 11 (68.8) | 12 (52.2) | 8 (53.3) | 7 (70.0) | 15 (71.4) |
| None | 1 (2.6) | 0 | 0 | 4 (25.0) | 1 (4.3) | 0 | 0 | 5 (23.8) |
| Unknown | 2 (5.1) | 0 | 0 | 0 | 0 | 1 (6.7) | 1 (10.0) | 0 |
| P-value | 0.858 | 0.297 | 0.529 | 0.106 | ||||
| Metastatic site, n (%) | ||||||||
| Lymph nodes | 19 (30.1) | 3 (15.8) | 1 (6.3) | 8 (24.3) | 10 (27.0) | 7 (38.9) | 4 (25.0) | 8 (17.4) |
| Local site | 15 (23.8) | 2 (10.5) | 1 (6.3) | 3 (9.1 | 10 (27.0) | 2 (11.1) | 3 (18.5) | 7 (15.2) |
| Bone | 8 (12.7) | 4 (21.0) | 3 (18.7) | 6 (18.2) | 7 (18.9) | 2 (11.1) | 2 (12.5) | 8 (17.4) |
| Lung and pleura | 7 (11.1) | 3 (15.8) | 4 (25.0) | 3 (9.1) | 3 (8.1) | 2 (11.1) | 3 (18.7) | 6 (13.0) |
| Liver | 7 (11.1) | 4 (21.0) | 3 (18.7) | 7 (21.2) | 3 (8.1) | 3 (16.7) | 4 (25.0) | 8 (17.4) |
| Brain | 3 (4.8) | 1 (5.3) | 2 (12.5) | 4 (12.1) | 2 (5.4) | 0 | 0 | 5 (10.9) |
| Gastrointestinal tract | 1 (1.6) | 1 (5.3) | 2 (12.5) | 1 (3.0) | 1 (2.7) | 1 (5.5) | 0 | 3 (6.5) |
| Other | 3 (4.8) | 1 (5.3) | 0 | 1 (3.0) | 1 (2.7) | 1 (5.5) | 0 | 1 (2.2) |